Skip to main content
Clinical Trials/NCT04662814
NCT04662814
Completed
Not Applicable

the Efficacy of Extracorporeal Shock Wave Therapy for Primary Dysmenorrhea

MTI University1 site in 1 country50 target enrollmentSeptember 12, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Dysmenorrhea
Sponsor
MTI University
Enrollment
50
Locations
1
Primary Endpoint
numerical rating scale
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

purpose of this study to investigate the effect of Extracorporeal shock wave therapy on pain and prostaglandin level in patient with primary dysmenorrhea

Detailed Description

This randomized controlled trial is to determine the effect of shock wave therapy in the treatment of primary dysmenorrhea. females are randomly assigned into 2 groups: group A SWT treatment plus dietary modification during PD (n=25) GROUP B:dietary modification only (n=25); Participants in group B will receive dietary modification for three successive months The numerical rating scale (NRS) and prostaglandin blood level will be recorded and evaluated before and after treatment.

Registry
clinicaltrials.gov
Start Date
September 12, 2020
End Date
January 27, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

shaimaa Mohamed hamed

principle investigator

MTI University

Eligibility Criteria

Inclusion Criteria

  • ages ranged between18 - 25 years old.
  • body mass index (BMI) will not exceed 30kg/m
  • females will be diagnosed by the physician as primary dysmenorrhea.

Exclusion Criteria

  • Secondary dysmenorrhea .
  • Mental health problem such as depression and anxiety.
  • Irregular periods

Outcomes

Primary Outcomes

numerical rating scale

Time Frame: 3 months

Numeric rating scale will be 10 cm digital line with 0 (zero) representing feeling no pain and 10 representing feeling the worst pain, was used to assess the severity of the pain before and after treatment for all females in both groups (A\&B). measurement will done twice first one at baseline(will be considered as pre treatment measure) and 2nd on e at 3rd menstrual cycle ( will be considered as post treatment measure)

Secondary Outcomes

  • prostaglandin(3months)

Study Sites (1)

Loading locations...

Similar Trials